Thursday, May 11 | 12-1 p.m. ET | Online
The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.
Olivia Dong, PhD
Senior Research Health Economist
RTI Health Solutions
Title: How Are Genetic Tests Evaluated for Clinical Use in the UK?
Learn more and register on the Precision Medicine Forum Series website.
Thursday, April 13 | 12-1 p.m. ET | Online
The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.
Kevin Shah, MD
Associate Professor of Medicine (General Internal Medicine)
Duke Department of Medicine
Title: Implementation and Impact of a Risk Stratified Prostate Cancer Screening Algorithm in Duke Primary Care
Watch the recording on the Precision Medicine Forum Series website.
Thursday, April 27 | 12-1 p.m. ET | Online
The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.
Michael Pencina, PhD
Vice Dean for Data Science
Duke University School of Medicine
Title: How do we make sure that health AI algorithms are in the service of humanity?
Learn more and register on the Precision Medicine Forum Series website.
Friday, February 17 | 10 a.m.-4:15 p.m. ET | Online
The U.S. Food and Drug Administration (FDA) – in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) – will host a one-day virtual public workshop entitled “Application of Artificial Intelligence and Machine Learning for Precision Medicine.”
The purpose of this workshop is to review current methodologies, opportunities, challenges, and best practices to address the rapidly changing landscape of artificial intelligence and machine learning in the setting of drug development and precision medicine.
Matteo Castrichini, Jasmine A Luzum, Naveen Pereira
Abstract
Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of CYP2C19 genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.
Keywords: CYP2C19; dual antiplatelet therapy; guided antiplatelet therapy; pharmacogenetics; pharmacogenomics; precision medicine.
Wednesday, February 22 | 9 a.m. ET | Virtual
This webinar, Transforming Health in Singapore Through Precision Medicine, will be presented by Prof. Patrick Tan.
Prof. Patrick Tan is the Executive Director of PRECISE. As Executive Director of PRECISE, Prof Tan is currently overseeing the implementation of Phase II of Singapore’s Precision Medicine Strategy, which aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions.
Visit the IHCC Educational Webinar Series webpage to learn more and register.
Please note: Registration is required for this event.
March 2-3 | Virtual & Orlando, FL
The University of Florida College of Pharmacy has partnered with GenomeWeb’s Precision Medicine Leaders’ Summit to produce this event, which will be in-person and live streamed.
Updates in Precision Medicine and Pharmacogenomics will highlight the evolving role of molecular profiling in guiding pharmacotherapy decision-making – from new developments in pharmacogenomics to the use of companion diagnostics, polygenic risk scores, and other biomarker strategies.
Visit the Updates in Precision Medicine conference website for more information and to register.
Thursday, February 23 | 12-1 p.m. ET | Virtual
The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.
Speaker: Michael J. Kelley, MD
Professor of Medicine (Medical Oncology)
Duke Department of Medicine
Learn more and register on the forum series website.
Thursday, February 9 | 12-1 p.m. ET | Virtual
The Duke Precision Medicine Program Forum Series features speakers from Duke and beyond working on innovative research in clinical, translational, and basic sciences.
Speaker: Michael Olivier, PhD
Professor, Molecular Medicine
Wake Forest University School of Medicine
Learn more and register on the forum series website.
GMKB